The novel Tenzing 7 delivery catheter designed to deliver intermediate catheters to the face of embolus without crossing: clinical performance predicted in anatomically challenging model.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 25 05 2020
revised: 28 07 2020
accepted: 28 07 2020
pubmed: 5 9 2020
medline: 27 7 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

In large vessel occlusionstroke, navigation of aspiration catheters (AC) can be impeded by vessel tortuosity and the ophthalmic artery origin. A novel tapered delivery catheter was designed to facilitate delivery without disturbing the embolus. We assessed AC deliverability in vitro and validated the observations in a first-in-human experience. In a vascular model with three challenging craniocervical scenarios, two commercial AC were advanced from the carotid to the middle cerebral artery by four neurointerventionalists. Catheter deliverability with standard microwire and microcatheter (MC) combinations and the Tenzing 7 (T7) Delivery Catheter (Route 92 Medical, San Mateo, CA) were compared. Operators rated aspects of catheter deliverability on a 5-point scale. Results were compared with device delivery patterns at a neurovascular center before and after clinical introduction of T7. In vitro, success rate and speed were higher with T7 (96%; mean 30±10 s) than with MC (65%; 72±47 s, p<0.001 each), with fewer interactions with the occlusion site (T7: 54% vs MC: 77%, p=0.004). T7 received superior ratings regarding carotid artery deflection (T7: 2, IQR1-3 vs MC: 3, IQR2-3, p<0.001), guide catheter pushback (T7: 2, IQR1-3 vs MC: 3, IQR3-3, p<0.001) and ophthalmic artery passage (T7: 1.5, IQR1-2 vs MC: 4, IQR3-5, p<0.001). Before introduction of T7 at a single center, delivery of AC to a large vessel occlusion without crossing was achieved in 15/123 cases (12%). With T7, this rate was 28/31 patients (90.3%). Compared with microcatheter and microwire combinations, T7 improves aspiration catheter delivery in vitro, minimizing the need to cross the occlusion. Initial clinical experience appears to validate the model's observations.

Sections du résumé

BACKGROUND BACKGROUND
In large vessel occlusionstroke, navigation of aspiration catheters (AC) can be impeded by vessel tortuosity and the ophthalmic artery origin. A novel tapered delivery catheter was designed to facilitate delivery without disturbing the embolus. We assessed AC deliverability in vitro and validated the observations in a first-in-human experience.
METHODS METHODS
In a vascular model with three challenging craniocervical scenarios, two commercial AC were advanced from the carotid to the middle cerebral artery by four neurointerventionalists. Catheter deliverability with standard microwire and microcatheter (MC) combinations and the Tenzing 7 (T7) Delivery Catheter (Route 92 Medical, San Mateo, CA) were compared. Operators rated aspects of catheter deliverability on a 5-point scale. Results were compared with device delivery patterns at a neurovascular center before and after clinical introduction of T7.
RESULTS RESULTS
In vitro, success rate and speed were higher with T7 (96%; mean 30±10 s) than with MC (65%; 72±47 s, p<0.001 each), with fewer interactions with the occlusion site (T7: 54% vs MC: 77%, p=0.004). T7 received superior ratings regarding carotid artery deflection (T7: 2, IQR1-3 vs MC: 3, IQR2-3, p<0.001), guide catheter pushback (T7: 2, IQR1-3 vs MC: 3, IQR3-3, p<0.001) and ophthalmic artery passage (T7: 1.5, IQR1-2 vs MC: 4, IQR3-5, p<0.001). Before introduction of T7 at a single center, delivery of AC to a large vessel occlusion without crossing was achieved in 15/123 cases (12%). With T7, this rate was 28/31 patients (90.3%).
CONCLUSION CONCLUSIONS
Compared with microcatheter and microwire combinations, T7 improves aspiration catheter delivery in vitro, minimizing the need to cross the occlusion. Initial clinical experience appears to validate the model's observations.

Identifiants

pubmed: 32883781
pii: neurintsurg-2020-016412
doi: 10.1136/neurintsurg-2020-016412
pmc: PMC8292588
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

722-726

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: ROUTE 92 MEDICAL & TENZING are registered trademarks of Route 92 Medical, Inc. T7 is a trademark of Route 92 Medical, Inc. Catheters and travel support for physicians participating in the laboratory experiments were supplied by Route 92 Medical, Inc.

Références

N Engl J Med. 2015 Jun 11;372(24):2285-95
pubmed: 25882376
J Neurointerv Surg. 2020 Feb;12(2):214-219
pubmed: 31320551
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Clin Neuroradiol. 2019 Dec;29(4):661-667
pubmed: 30191252
J Neurointerv Surg. 2019 May;11(5):439-442
pubmed: 30472671
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
J Neurointerv Surg. 2016 Feb;8(2):197-202
pubmed: 25540180
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
J Neurointerv Surg. 2015 Sep;7(9):628-33
pubmed: 24996435
Lancet. 2019 Mar 9;393(10175):998-1008
pubmed: 30860055
J Stroke. 2019 Jan;21(1):2-9
pubmed: 30732438
AJNR Am J Neuroradiol. 2017 Dec;38(12):2277-2281
pubmed: 29025728
JAMA. 2017 Aug 1;318(5):443-452
pubmed: 28763550
J Neurointerv Surg. 2014 Apr 1;6(3):231-7
pubmed: 23624315
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510

Auteurs

Andreas Maximilian Frölich (AM)

Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany a.froelich@uke.de.

Warren Kim (W)

Radiology, California Pacific Medical Center, San Francisco, California, USA.

Knut Stribrny (K)

Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Olav Jansen (O)

Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany.

Markus Möhlenbruch (M)

Neuroradiology, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany.

Istvan Szikora (I)

Neurointerventions, National Institute of Neurosciences, Budapest, Hungary.

Fritz Wodarg (F)

Department of Radiology and Neuroradiology, Universitatsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany.

Jens Fiehler (J)

Department of Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany.

Kim Otto (K)

Route 92 Medical, Inc, San Mateo, California, USA.

Tony Chou (T)

Route 92 Medical, Inc, San Mateo, California, USA.

Jan Hendrik Buhk (JH)

Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Joey English (J)

Radiology, California Pacific Medical Center, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH